+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma



Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma



World Journal of Surgery 20(3): 326-331



To clarify the effect of preoperative transcatheter arterial oily chemoembolization (TAOE) for resectable hepatocellular carcinoma (HCC) on long-term survival after curative resection, we retrospectively evaluated 60 patients with and 68 patients without preoperative TAOE. Although there was no substantial difference in the clinical backgrounds between the two groups, the 5-year survival rate was lower for the patients with preoperative TAOE than for those without TAOE: 24% versus 63%, respectively (p < 0.05). A worse survival rate was particularly observed for the cirrhotic patients with TAOE than for those without TAOE: 35% and 72% at 4 years, respectively (p < 0.01). As the cause of death, liver failure and gastrointestinal bleeding were more frequent in the patients with TAOE (13.3% versus 1.5%;p < 0.05). Although the TAOE seemed to retard intrahepatic recurrence during the first 1.5 years after operation (1.7% versus 10.3%;p < 0.05), the overall cancer death rate was similar between the two groups (18.3% versus 11.8%). Therefore we suggest that preoperative TAOE must not be performed for resectable HCC as a routine procedure, particularly in patients with cirrhosis. A prospective randomized trial is warranted to elucidate the merits and demerits of preoperative TAOE for surgically resectable HCC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047288023

Download citation: RISBibTeXText

PMID: 8661839

DOI: 10.1007/s002689900052


Related references

Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World Journal of Surgery 27(12): 1295-1299, 2003

Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. British Journal of Surgery 82(1): 122-126, 1995

Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis. Annals of Hepatology 13(4): 394-402, 2015

Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International 1(4): 523-526, 2003

Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. Bmc Gastroenterology 13: 51, 2013

Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. European Journal of Surgical Oncology 32(7): 773-779, 2006

Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. Cancer ChemoTherapy and Pharmacology 23(Suppl.): S29-S32, 1989

The Negative Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-Term Outcomes for Resectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Yonago Acta Medica 59(4): 270-278, 2017

Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence. Journal of Cancer 9(16): 2778-2785, 2018

Studies on the chemotherapy with 5 fluorouracil in transcatheter arterial chemoembolization tae treated patients with resectable or non resectable hepatocellular carcinoma. Cancer Chemotherapy & Pharmacology 23(SUPPL): S29-S32, 1989

Hepatic arterial collaterals after transcatheter oily chemoembolization of hepatocellular carcinoma. Journal of the Medical Association of Thailand 84(1): 75-84, 2001

Low-output radiofrequency ablation combined with transcatheter arterial oily-chemoembolization for hepatocellular carcinoma. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 65(2): 124-126, 2005

Delayed formation of liver abscess following transcatheter arterial oily-chemoembolization for hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi 90(11): 2931-2935, 1993

Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 11(3): 315-322, 1999

Lipiodol transcatheter arterial chemoembolization for non-resectable hepatocellular carcinoma--multicenter cooperative study. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(2): 227-232, 1990